全文获取类型
收费全文 | 8134篇 |
免费 | 473篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 282篇 |
妇产科学 | 192篇 |
基础医学 | 1246篇 |
口腔科学 | 173篇 |
临床医学 | 719篇 |
内科学 | 1683篇 |
皮肤病学 | 246篇 |
神经病学 | 860篇 |
特种医学 | 167篇 |
外科学 | 623篇 |
综合类 | 67篇 |
一般理论 | 3篇 |
预防医学 | 668篇 |
眼科学 | 185篇 |
药学 | 770篇 |
中国医学 | 11篇 |
肿瘤学 | 679篇 |
出版年
2024年 | 8篇 |
2023年 | 65篇 |
2022年 | 215篇 |
2021年 | 350篇 |
2020年 | 203篇 |
2019年 | 215篇 |
2018年 | 280篇 |
2017年 | 195篇 |
2016年 | 276篇 |
2015年 | 273篇 |
2014年 | 318篇 |
2013年 | 462篇 |
2012年 | 688篇 |
2011年 | 668篇 |
2010年 | 351篇 |
2009年 | 301篇 |
2008年 | 481篇 |
2007年 | 524篇 |
2006年 | 500篇 |
2005年 | 459篇 |
2004年 | 481篇 |
2003年 | 407篇 |
2002年 | 382篇 |
2001年 | 48篇 |
2000年 | 45篇 |
1999年 | 43篇 |
1998年 | 50篇 |
1997年 | 51篇 |
1996年 | 39篇 |
1995年 | 23篇 |
1994年 | 26篇 |
1993年 | 22篇 |
1992年 | 17篇 |
1991年 | 17篇 |
1990年 | 10篇 |
1989年 | 17篇 |
1988年 | 10篇 |
1987年 | 6篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 9篇 |
1983年 | 12篇 |
1982年 | 13篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1976年 | 4篇 |
1975年 | 4篇 |
1974年 | 6篇 |
排序方式: 共有8642条查询结果,搜索用时 0 毫秒
91.
Favorable four‐yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation‐associated HUS 下载免费PDF全文
Ryszard Grenda Wioletta Jarmużek Jacek Rubik Sylwester Prokurat Monika Miklaszewska Dorota Drozdz Katarzyna Zachwieja Gianluigi Ardissino Johannes Hofer 《Pediatric transplantation》2015,19(6):E130-E134
aHUS is a clinical challenge for successful renal transplantation. Case report: A 14‐yr‐old girl lost her kidneys at the age of 7, due to CFH antibodies and CFH‐related protein (CFHR1/CFHR3) homozygous deletion‐associated aHUS. CFH, CFI, and MCP gene mutations were excluded. The patient was a candidate for renal transplantation despite persistent presence of CFH antibodies (up to 539 AU/mL). Treatment with MMF, IVIG, and repeated PF (n = 8) was introduced while being placed on urgent waiting list. Three years after aHUS onset, the patient underwent the deceased donor renal transplantation “under cover” of PF, as PF was performed directly prior to surgery and, then, PFs were repeated up to overall 14 sessions. Quadruple immunosuppression (basiliximab + tacrolimus + MMF + prednisolone) was used. Moderate symptoms of aHUS (hemolysis, low platelets, and low C3) were present within first seven days post‐transplant and then normalized with PF therapy. The patient remained stable during four yr of further follow‐up after transplantation. Conclusion: Specific pre‐ and post‐transplant management allowed successful renal transplantation in a CFH antibody‐positive patient. 相似文献
92.
93.
The PCBP1 gene encoding poly(rc) binding protein i is recurrently mutated in Burkitt lymphoma 下载免费PDF全文
Rabea Wagener Sietse M. Aukema Matthias Schlesner Andrea Haake Birgit Burkhardt Alexander Claviez Hans G. Drexler Michael Hummel Markus Kreuz Markus Loeffler Maciej Rosolowski Cristina Lpez Peter Mller Julia Richter Marius Rohde Matthew J. Betts Robert B. Russell Stephan H. Bernhart Steve Hoffmann Philip Rosenstiel Markus Schilhabel Monika Szczepanowski Lorenz Trümper Wolfram Klapper Reiner Siebert 《Genes, chromosomes & cancer》2015,54(9):555-564
The genetic hallmark of Burkitt lymphoma is the translocation t(8;14)(q24;q32), or one of its light chain variants, resulting in IG‐MYC juxtaposition. However, these translocations alone are insufficient to drive lymphomagenesis, which requires additional genetic changes for malignant transformation. Recent studies of Burkitt lymphoma using next generation sequencing approaches have identified various recurrently mutated genes including ID3, TCF3, CCND3, and TP53. Here, by using similar approaches, we show that PCBP1 is a recurrently mutated gene in Burkitt lymphoma. By whole‐genome sequencing, we identified somatic mutations in PCBP1 in 3/17 (18%) Burkitt lymphomas. We confirmed the recurrence of PCBP1 mutations by Sanger sequencing in an independent validation cohort, finding mutations in 3/28 (11%) Burkitt lymphomas and in 6/16 (38%) Burkitt lymphoma cell lines. PCBP1 is an intron‐less gene encoding the 356 amino acid poly(rC) binding protein 1, which contains three K‐Homology (KH) domains and two nuclear localization signals. The mutations predominantly (10/12, 83%) affect the KH III domain, either by complete domain loss or amino acid changes. Thus, these changes are predicted to alter the various functions of PCBP1, including nuclear trafficking and pre‐mRNA splicing. Remarkably, all six primary Burkitt lymphomas with a PCBP1 mutation expressed MUM1/IRF4, which is otherwise detected in around 20–40% of Burkitt lymphomas. We conclude that PCBP1 mutations are recurrent in Burkitt lymphomas and might contribute, in cooperation with other mutations, to its pathogenesis. © 2015 Wiley Periodicals, Inc. 相似文献
94.
95.
Tomasz Cytlak Monika Skibiska Patrycja Kaczmarek Marcin Ka
mierczak Magdalena Rapp Maciej Kubicki Henryk Koroniak 《RSC advances》2018,8(22):11957
Direct conversion of the α-hydroxyl group by para-toluenesulfonamide to yield α-(N-tosyl)aminophosphonates is reported. α-Aminophosphonates 23a,b–37a,b were obtained from the corresponding α-hydroxyphosphonates 6a,b–21a,b in the presence of K2CO3, via the retro-Abramov reaction of the appropriate aldehydes, 1–5. The subsequent formation of imines with simultaneous addition of diethyl phosphite provided access to the α-sulfonamide phosphonates 23a,b–37a,b with better diastereoselectivity than in the case of the Pudovik reaction. The mechanism for this transformation is proposed herein. When Cbz N-protected aziridine 9a,b and phenylalanine analogue 12a,b were exploited, intramolecular substitution was observed, leading to the corresponding epoxide 38 as the sole product, or oxazolidin-2-one 39 as a minor product. Analogous substitution was not observed in the case of proline 18a,b and serine 21a,b derivatives.The reaction mechanism and diastereoselectivity of the direct transformation of α-hydroxyphosphonates 6a,b–21a,b by para-toluenesulfonamide, yielding α-(N-tosyl)aminophosphonates 23a,b–37a,b under K2CO3 conditions are presented. 相似文献
96.
97.
Geno J. Merli Judd E. Hollander Patrick Lefebvre Monika K. Raut William H. Olson 《Hospital practice (1995)》2015,43(2):85-93
Background. Compared to warfarin, the non-vitamin K antagonist oral anticoagulant rivaroxaban may have advantages in treating patients with venous thromboembolism, because injectable bridging therapy and routine laboratory monitoring are not required. The objective of this study was to compare the rate of hospitalization in patients treated with rivaroxaban after its introduction with what it would have been before the introduction of rivaroxaban. Methods. A retrospective claims analysis was conducted using the MarketScan Hospital Drug Database from January 2011 to December 2013. Adult patients with a primary diagnosis of deep vein thrombosis (DVT) treated with rivaroxaban or low-molecular-weight heparin (LMWH) bridged to warfarin during the first day of an evaluation at a hospital were identified. Based on propensity-score methods, historical LMWH/warfarin patients (i.e., patients who received LMWH/warfarin before the approval of rivaroxaban) were matched 4:1 to rivaroxaban patients, and the rates of hospitalization were compared. Results. All rivaroxaban-treated patients (n = 134) in the database were well matched with four historical LMWH/warfarin-treated patients (n = 536). Among the rivaroxaban cohort, 60% of the patients were admitted to the hospital, compared to 82% of the historical patients treated with LMWH/warfarin in the matched cohort. The difference was statistically significant and corresponded to a 27% reduction in hospital admissions (rate ratio [95% confidence interval]: 0.73 [0.62–0.84]). Hospital admission rates adjusted for time-trend analyses also led to similar results. Conclusion. The availability of rivaroxaban significantly reduced the hospitalization rate in patients with DVT treated with rivaroxaban compared to what it would have been if only LMWH/warfarin were available. 相似文献
98.
99.
Limperger Verena Kenet Gili Kiesau Bettina Köther Max Schmeiser Malin Langer Florian Juhl David Shneyder Maria Franke Andre Klostermeier Ulrich K. Mesters Rolf Rühle Frank Stoll Monika Steppat Dagmar Kowalski Dorothee Rocke Angela Kuta Piotr Bajorat Tido Torge Antje Neuner Bruno Junker Ralf Nowak-Göttl Ulrike 《Journal of thrombosis and thrombolysis》2021,51(2):494-501
Journal of Thrombosis and Thrombolysis - The role of the A>G polymorphism at position 19911 in the prothrombin gene (factor [F] 2 at rs3136516) as a risk factor for venous thromboembolism... 相似文献
100.